Rosavin

Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis^[1][2][3][4].
In Vitro:Rosavin (0-100 μM, 72 h) shows more protective effect on the cell viability at a low concentration in the irradiated intestinal epithelioid cell lines^[1].
In Vivo:Rosavin (2 ml, 200 mg/kg, i.g., 7 days) significantly increases survival rate in irradiated rats and improves the intestinal structure and function on radiation-induced intestinal injury^[1].
Rosavin (2 ml, 200 mg/kg, i.g., assay at day 1, 3, 5, and 7 day after radiation) significantly reduces the level of TNF-α, IL-1β, neutrophil infiltration and increases the level of IL-10 in irradiated rats, thereby attenuates inflammatory damage caused by radiation. Additionally, Rosavin exerts anti-oxidation property in irradiated rats^[1][2].
Rosavin (2.5, 5, 10 mg/kg, infusion, daily for 3 days) protects against Ischemia–reperfusion (I/R)-induced cerebral injury in vivo and attenuates I/R-induced inflammation both in mice and HBMVECs. Additionally, Rosavin exhibits I/R-induced apoptosis in mouse brain tissues and significantly suppresses the activation of the phosphorylation of ERK1/2, p38 and JNK1/2 both in vivo and in vitro^[3].